Loading
A phase 2 trial of Dexamethasone, Daratumumab, Venetoclax in multiple myeloma, run by AbbVie, active and no longer recruiting.
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT03314181 by AbbVie, with 156 participants enrolled, started 2018-04-02 and due to reach its primary completion in 2031-05. Interventions recorded: Dexamethasone, Daratumumab, Venetoclax, Bortezomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Dexamethasone.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Dexamethasone.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Bortezomib, Dexamethasone.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Bortezomib, Dexamethasone.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Bortezomib, Dexamethasone.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, BCL-2 inhibitors, Daratumumab, Dexamethasone.
Shares BCL-2 inhibitors, Relapsed or refractory multiple myeloma, Venetoclax, Multiple myeloma.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, AbbVie (incl. ImmunoGen, Capstan), Dexamethasone.